22.70
-7.93 (-25.89%)
| Previous Close | 30.63 |
| Open | 21.27 |
| Volume | 12,640,762 |
| Avg. Volume (3M) | 1,570,079 |
| Market Cap | 1,447,674,368 |
| Price / Book | 2.71 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Diluted EPS (TTM) | -3.00 |
| Total Debt/Equity (MRQ) | 10.18% |
| Current Ratio (MRQ) | 27.68 |
| Operating Cash Flow (TTM) | -155.26 M |
| Levered Free Cash Flow (TTM) | -97.14 M |
| Return on Assets (TTM) | -23.46% |
| Return on Equity (TTM) | -39.49% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Vera Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.0 |
| Average | 3.13 |
|
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 5.16% |
| % Held by Institutions | 108.90% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Commodore Capital Lp | 31 Mar 2025 | 2,561,782 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 100.00 (Cantor Fitzgerald, 340.53%) | Buy |
| Median | 70.00 (208.37%) | |
| Low | 26.00 (Wedbush, 14.54%) | Hold |
| Average | 66.50 (192.95%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 27.18 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 02 Jun 2025 | 85.00 (274.45%) | Buy | 31.74 |
| 05 May 2025 | 75.00 (230.40%) | Buy | 25.53 | |
| Scotiabank | 02 Jun 2025 | 55.00 (142.29%) | Buy | 31.74 |
| Cantor Fitzgerald | 07 May 2025 | 100.00 (340.53%) | Buy | 22.62 |
| Wedbush | 07 May 2025 | 26.00 (14.54%) | Hold | 22.62 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Jun 2025 | Announcement | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 04 Jun 2025 | Announcement | Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference |
| 03 Jun 2025 | Announcement | Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans |
| 02 Jun 2025 | Announcement | Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy |
| 09 May 2025 | Announcement | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 06 May 2025 | Announcement | Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results |
| 09 Apr 2025 | Announcement | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 03 Apr 2025 | Announcement | Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |